Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 13/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | CDC42 | P60953 | 1/20 | 0.43 |
| ▸ | RAC1 | P63000 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597746 | 1.00 | AKR1C3 (0.58) | AKR1C3AKR1C2TSHRMAPTALDH1A1 | |
| SCHEMBL31212652 | 0.87 | TSHR (0.57) | AKR1C3AKR1C2TSHRMAPTALDH1A1 | |
| SCHEMBL2597759 | 0.85 | TSHR (0.58) | AKR1C3AKR1C2TSHRMAPTALDH1A1 | |
| SCHEMBL2597758 | 0.85 | TSHR (0.58) | AKR1C3AKR1C2TSHRMAPTALDH1A1 | |
| SCHEMBL4142382 | 0.84 | GRM8 (0.50) | AKR1C3AKR1C2TSHRPTGS1PTGS2 | |
| SCHEMBL5948037 | 0.83 | AKR1C3 (0.59) | AKR1C3AKR1C2TSHRMAPTMEN1 | |
| SCHEMBL30192831 | 0.83 | AKR1C3 (0.59) | AKR1C3AKR1C2TSHRMAPTMEN1 | |
| SCHEMBL5948033 | 0.83 | AKR1C3 (0.59) | AKR1C3AKR1C2TSHRMAPTMEN1 | |
| SCHEMBL29231640 | 0.83 | AKR1C3 (0.59) | AKR1C3AKR1C2TSHRMAPTMEN1 | |
| SCHEMBL27297826 | 0.83 | AKR1C3 (0.47) | AKR1C3AKR1C2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | AKR1C3 1357/4885AKR1C2 1698/4885TSHR 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.